- Home
- SOPH vs GNFT Comparison
SOPH vs GNFT Comparison
Compare SOPH & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- GNFT
- Stock Information
- Founded
- SOPH 2011
- GNFT 1999
- Country
- SOPH Switzerland
- GNFT France
- Employees
- SOPH N/A
- GNFT N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPH Health Care
- GNFT Health Care
- Exchange
- SOPH Nasdaq
- GNFT Nasdaq
- Market Cap
- SOPH 226.6M
- GNFT 189.6M
- IPO Year
- SOPH 2021
- GNFT 2019
- Fundamental
- Price
- SOPH $3.26
- GNFT $3.80
- Analyst Decision
- SOPH Strong Buy
- GNFT Strong Buy
- Analyst Count
- SOPH 3
- GNFT 1
- Target Price
- SOPH $7.00
- GNFT $13.00
- AVG Volume (30 Days)
- SOPH 21.3K
- GNFT 9.8K
- Earning Date
- SOPH 11-05-2024
- GNFT 09-19-2024
- Dividend Yield
- SOPH N/A
- GNFT N/A
- EPS Growth
- SOPH N/A
- GNFT N/A
- EPS
- SOPH N/A
- GNFT 0.47
- Revenue
- SOPH $64,488,000.00
- GNFT $86,225,222.00
- Revenue This Year
- SOPH $7.20
- GNFT $155.44
- Revenue Next Year
- SOPH $15.71
- GNFT N/A
- P/E Ratio
- SOPH N/A
- GNFT $7.53
- Revenue Growth
- SOPH 9.85
- GNFT 175.45
- 52 Week Low
- SOPH $2.70
- GNFT $3.31
- 52 Week High
- SOPH $7.37
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SOPH 46.64
- GNFT 29.24
- Support Level
- SOPH $3.06
- GNFT $3.63
- Resistance Level
- SOPH $3.47
- GNFT $3.88
- Average True Range (ATR)
- SOPH 0.18
- GNFT 0.10
- MACD
- SOPH -0.00
- GNFT 0.02
- Stochastic Oscillator
- SOPH 45.45
- GNFT 15.30
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.